200 related articles for article (PubMed ID: 35697393)
1. Nonstimulant Treatments for ADHD.
Newcorn JH; Krone B; Dittmann RW
Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):417-435. PubMed ID: 35697393
[TBL] [Abstract][Full Text] [Related]
2. Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.
Cutler AJ; Mattingly GW; Jain R; O'Neal W
CNS Spectr; 2022 Apr; 27(2):199-207. PubMed ID: 33121553
[TBL] [Abstract][Full Text] [Related]
3. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Radonjić NV; Bellato A; Khoury NM; Cortese S; Faraone SV
CNS Drugs; 2023 May; 37(5):381-397. PubMed ID: 37166701
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Chan E; Fogler JM; Hammerness PG
JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder.
Childress A; Burton S
Expert Opin Drug Metab Toxicol; 2022 Jun; 18(6):357-366. PubMed ID: 35848085
[TBL] [Abstract][Full Text] [Related]
6. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder.
Price MZ; Price RL
CNS Drugs; 2023 Jul; 37(7):655-660. PubMed ID: 37430151
[TBL] [Abstract][Full Text] [Related]
7. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
Sallee FR
Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Huang YS; Tsai MH
CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
[TBL] [Abstract][Full Text] [Related]
9. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Jain R; Katic A
Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
[TBL] [Abstract][Full Text] [Related]
10. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents.
Childress AC; Berry SA
Drugs; 2012 Feb; 72(3):309-25. PubMed ID: 22316347
[TBL] [Abstract][Full Text] [Related]
12. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
13. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
[TBL] [Abstract][Full Text] [Related]
16. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Mattingly GW; Anderson RH
CNS Spectr; 2016 Dec; 21(S1):45-59. PubMed ID: 28044946
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Sohn M; Talbert J; Moga DC; Blumenschein K
Atten Defic Hyperact Disord; 2016 Sep; 8(3):149-58. PubMed ID: 27143026
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants.
Childress A
Expert Opin Pharmacother; 2024 May; 25(7):853-866. PubMed ID: 38771653
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
Lachaine J; Beauchemin C; Sasane R; Hodgkins PS
Postgrad Med; 2012 May; 124(3):139-48. PubMed ID: 22691908
[TBL] [Abstract][Full Text] [Related]
20. Changes and challenges: managing ADHD in a fast-paced world.
Manos MJ; Tom-Revzon C; Bukstein OG; Crismon ML
J Manag Care Pharm; 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16. PubMed ID: 18062734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
